Tag: Syngene
Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...
The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period
Syngene International to acquire stake in O2 Renewable Energy II
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
Syngene International forms a new subsidiary
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
Syngene International & Amgen extend their collaboration until 2026
Under the extended contract, the dedicated R&D center, ‘Syngene Amgen Research and Development Center’ (SARC), will continue to conduct drug discovery and development projects as part of Amgen’s global R&D program
Syngene makes senior-level appointments to its core team
Alex Del Priore has been appointed as the Senior Vice President, Manufacturing Services. Alan Collis joins as the Vice President, Integrated Drug Discovery services......................
Syngene clocks 12% growth in FY21 revenue at Rs. 2,184 crore
Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year......................
Industry discusses emerging trends at BioPharma World. IE 2021
Guest of Honour Kris Gopalakrishnan, Chairman, Axilor Ventures & Co-Founder; Infosys & Dr. Dinesh Dua, ED, Nectar Lifesciences & Chairman BioPharma World. IE 2021 felicitated the award winners..........................
Syngene enters into 5-year strategic collaboration with Deerfield Discovery & Development
This five-year collaboration aims to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.....................
Syngene Q2 operations revenue stands at INR 519 Crore, up 12%...
The company posted quarterly total revenue of INR 533 Crore compared to INR 485 Crore in the corresponding quarter of last year. EBITDA for the quarter was up 6% to INR 169 Crore while PAT was up 2% to INR 84 Crore..................
Syngene joins global industry consortium to accelerate collaborative research in COVID-19...
The consortium led by Bristol Myers Squibb brings together a diverse group of companies with synergistic areas of expertise................